Sign In
Buy DNLI
$19.66
+0.310 (+1.60%)
At Close: Jun 03, 2026
Denali Therapeutics Inc. (DNLI) Reports Q2 Loss, Tops Revenue Estimates
09:45pm, Friday, 07'th Aug 2020
Denali Therapeutics Inc. (DNLI) delivered earnings and revenue surprises of 8.20% and 57.60%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Denali Therapeutics Reports Second Quarter 2020 Financial Results and Business Highlights
08:30pm, Friday, 07'th Aug 2020
SOUTH SAN FRANCISCO, Calif., Aug. 07, 2020 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cro
Illumina Revenue Decline, And Other News: The Good, Bad And Ugly Of Biopharma (NASDAQ:ILMN)
07:31pm, Friday, 07'th Aug 2020
Illumina stock tumbles as quarterly numbers decline. Roche stumbles on Phase III Tecentriq update.
The Daily Biotech Pulse: Novavax Vaccine Deals, Trevena Awaits FDA Decision, 2 IPOs
12:00am, Friday, 07'th Aug 2020
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 6)
ADiTx Therapeutics Inc (NASDAQ: ADTX) (announced introduction of AditxtScore for COVID-19 to be used in detecting...
Biogen, Denali Announce Billion-Dollar Collaboration On Parkinson's Treatment
08:19pm, Thursday, 06'th Aug 2020
Biogen and Denali Therapeutics early Thursday announced a billion-dollar collaboration to move forward on testing on a Denali treatment for Parkinson's disease, sending DNLI stock soaring.
Denali Therapeutics stock rockets into record territory after Biogen investment and collaboration
01:13pm, Thursday, 06'th Aug 2020
Shares of Denali Therapeutics Inc. rocketed 29% into record territory in premarket trading Thursday, after Biogen Inc. announced a $465 million equity investment as part of a collaboration on Denali
Denali Therapeutics Announces Decision to Advance DNL151 into Late Stage Clinical Studies in Parkinson’s Patients
12:07pm, Thursday, 06'th Aug 2020
* DNL151 selected to advance into two late stage studies in Parkinson’s disease in patients with a kinase activating mutation in LRRK2 and in patients with sporadic disease * Denali and collabora
Why Shares of Denali Therapeutics Are Skyrocketing
12:00am, Thursday, 06'th Aug 2020
Shares of Denali Therapeutics Inc (NASDAQ: DNLI) are racing toward their 52-week high following a clinical pipeline update concerning the company's Parkinson's disease...
Denali Therapeutics Announces Phase 1b Study by Partner Sanofi of RIPK1-Inhibitor DNL758 (SAR443122) in COVID-19 Patients
01:00pm, Wednesday, 29'th Jul 2020
* Dosing of DNL758 (SAR443122) has commenced in a randomized, double-blind, placebo-controlled Phase 1b trial to evaluate safety and effect on the immune system in severe COVID-19 * DNL758, discovere
Denali Therapeutics Inc. (DNLI) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
04:32pm, Tuesday, 28'th Jul 2020
Denali Therapeutics Inc. (DNLI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NFL star Bobby Wagner joining former Microsoft, Amazon execs in Seattle-based tech fund
02:00pm, Tuesday, 28'th Jul 2020
The Seattle Seahawks linebacker will join investment firm Fuse Venture Partners to assist early-stage e-commerce companies.
Denali Therapeutics (NASDAQ:DNLI) Rating Lowered to Hold at BidaskClub
05:32am, Saturday, 18'th Jul 2020
BidaskClub cut shares of Denali Therapeutics (NASDAQ:DNLI) from a buy rating to a hold rating in a research report sent to investors on Tuesday morning, BidAskClub reports. Other equities research ana
Flagship Pioneering's Scientists Invent a New Category of Genome Engineering Technology: Gene Writing
12:00pm, Tuesday, 07'th Jul 2020
Flagship Pioneering today announced the unveiling of Tessera Therapeutics, Inc. a new company with the mission of curing disease by writing in the code of life. Tessera is pioneering Gene Writing™,
Denali Therapeutics Inc (NASDAQ:DNLI) Given Average Rating of “Buy” by Analysts
03:38am, Sunday, 05'th Jul 2020
Shares of Denali Therapeutics Inc (NASDAQ:DNLI) have been given an average rating of “Buy” by the fifteen ratings firms that are currently covering the stock, Marketbeat reports. Four research ana
Hedge Funds Have Never Been This Bullish On Denali Therapeutics Inc. (DNLI)
11:06pm, Sunday, 28'th Jun 2020
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and succes
